Nantahala Capital Management LLC Acquires New Shares in ADMA Biologics Inc $ADMA

Nantahala Capital Management LLC acquired a new position in shares of ADMA Biologics Inc (NASDAQ:ADMA) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 2,359,993 shares of the biotechnology company’s stock, valued at approximately $19,753,141. Nantahala Capital Management LLC owned about 1.05% of ADMA Biologics as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Summit Securities Group LLC acquired a new stake in ADMA Biologics in the fourth quarter valued at $29,000. iSAM Funds UK Ltd acquired a new position in shares of ADMA Biologics during the 3rd quarter worth $34,000. Morse Asset Management Inc acquired a new position in shares of ADMA Biologics during the 4th quarter worth $44,000. Nkcfo LLC purchased a new stake in shares of ADMA Biologics in the 4th quarter worth about $47,000. Finally, EverSource Wealth Advisors LLC boosted its position in shares of ADMA Biologics by 385.8% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,745 shares of the biotechnology company’s stock worth $50,000 after buying an additional 2,180 shares in the last quarter. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

ADMA has been the topic of a number of research reports. Zacks Research cut shares of ADMA Biologics from a “hold” rating to a “strong sell” rating in a research note on Tuesday, August 4th. Mizuho cut their target price on shares of ADMA Biologics from $20.00 to $17.00 and set an “outperform” rating for the company in a research report on Wednesday, July 15th. Canaccord Genuity Group reduced their price target on shares of ADMA Biologics from $21.00 to $18.00 and set a “buy” rating on the stock in a report on Thursday, May 7th. Weiss Ratings reiterated a “hold (c)” rating on shares of ADMA Biologics in a research report on Thursday, June 18th. Finally, Wall Street Zen cut shares of ADMA Biologics from a “buy” rating to a “hold” rating in a research note on Monday, May 4th. Three research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, ADMA Biologics currently has a consensus rating of “Hold” and an average price target of $18.67.

ADMA Biologics Stock Performance

NASDAQ ADMA opened at $9.34 on Friday. The company has a quick ratio of 3.81, a current ratio of 6.97 and a debt-to-equity ratio of 0.49. ADMA Biologics Inc has a fifty-two week low of $7.21 and a fifty-two week high of $20.46. The business has a fifty day moving average of $9.07 and a 200-day moving average of $10.54. The stock has a market cap of $2.09 billion, a price-to-earnings ratio of 13.34 and a beta of 0.74.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.16 EPS for the quarter, meeting analysts’ consensus estimates of $0.16. The business had revenue of $124.39 million for the quarter, compared to analyst estimates of $125.34 million. ADMA Biologics had a return on equity of 40.17% and a net margin of 32.98%.The business’s revenue for the quarter was up 2.0% compared to the same quarter last year. During the same quarter last year, the company earned $0.14 earnings per share. As a group, analysts predict that ADMA Biologics Inc will post 0.78 earnings per share for the current fiscal year.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.